Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Applied Dna Scns (NQ: APDN )

0.3503 -0.0097 (-2.69%)
Streaming Delayed Price Updated: 11:32 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 59,420
Open 0.3600
Bid (Size) 0.3500 (87)
Ask (Size) 0.3501 (1)
Prev. Close 0.3600
Today's Range 0.3500 - 0.3800
52wk Range 0.3601 - 1.860
Shares Outstanding 16,978,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Performance

YTD
-43.51%
-43.51%
1 Month
-20.39%
-20.39%
3 Month
-41.72%
-41.72%
6 Month
-65.99%
-65.99%
1 Year
-65.99%
-65.99%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Via ACCESSWIRE
Recap: Applied DNA Sciences Q1 Earnings
Via Benzinga
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Via ACCESSWIRE
Earnings Scheduled For February 8, 2024
Via Benzinga
Earnings Preview For Applied DNA Sciences
Via Benzinga
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Via ACCESSWIRE
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Applied DNA Sciences: Q4 Earnings Insights
Via Benzinga
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
Via ACCESSWIRE
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
Via ACCESSWIRE
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Via ACCESSWIRE
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For December 7, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Via ACCESSWIRE
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.